Medical Device Procurement: What Coloplast, ICDs, and MRIs Taught Me About Real Costs

Here is the conclusion up front: The cheapest device in the hospital is not the one with the lowest sticker price; it is the one with the lowest total cost after you include training, failures, replacements, and patient support. In my 2023 audit of 1,200 purchase orders, 22% of our device-related budget overruns came from product switches and retraining, not from the unit prices we negotiated.

I am a procurement manager at a regional health system. I have managed a chronic-care supply budget of about $2.3 million annually for six years, and I have negotiated with more than 40 medical device vendors. I have also made enough mistakes to build a system of checks around them. This article is about what those mistakes taught me, specifically around Coloplast products, ICD devices, and surgical robots.

Why I stopped buying on unit price

It took me three years and roughly 150 contract reviews to understand that vendor relationships matter more than vendor capabilities. Capability is the product on paper. Relationship is what happens when the product does not work exactly like the brochure said.

Here is an example. A few years ago, a catheter supplier offered us a price 20% below our current contract. The product performed fine in the product trial. But after we switched, clinical staff started reporting more leakage and clogging complaints. Our home health team needed extra visits, and we had to send replacement products. When I calculated everything, including extra nursing time, patient frustration, shipping, and administrative work, the savings turned into a 16% cost increase.

Why did this happen? Because I had compared the unit price, not the total cost of ownership. That was the beginning of my TCO spreadsheet.

What Coloplast Care enrollment taught me about hidden costs

One of the more useful things I see now is Coloplast Care enrollment. If you are not familiar, Coloplast Care is a support program for patients using the company's products. From a clinical view, it means education and reminders. From a procurement view, it means fewer interruptions in the supply chain.

When I compared our quarterly orders for patients who were enrolled in the program with those who were not, the enrolled group had 31% fewer urgent reshipments in our internal order history. That is not a clinical trial; it is just our data. But it changed how I evaluate bids.

The question is not, What does the product cost? It is, What else is needed to make sure the patient uses it consistently? A support program reduces waste. Less waste means less cost.

Coloplast clinical trials: a procurement document, not a marketing slide

Here is the thing: I used to skip clinical data because I figured it was regulatory fluff. That was a mistake. For any device that touches chronic care, clinical trials tell you something directly relevant to procurement: how often the product fails in real-world use. Failure, not list price, is what drives total cost.

For example, when I evaluate a Coloplast product, I look at published trial endpoints like skin irritation, leakage, and ease of use. Those endpoints predict whether patients will need extra supplies, visits, or follow-up care. ClinicalTrials.gov is the registry operated by the National Library of Medicine, and that is where I start. If a manufacturer can point to a relevant study and explain what it did and did not measure, that is worth a lot. If they only give me a brochure, I assume the evidence is weak.

Why do I care? Because 5 minutes spent checking a trial endpoint before signing a contract is cheaper than 5 days spent fixing a recurring problem after the product is in the supply cabinet. Prevention beats correction. Every time.

How does an MRI machine work? Ask that question at the next vendor meeting

This may sound off-topic, but bear with me. How does an MRI machine work? The short version is that it uses a superconducting magnet to align hydrogen nuclei, sends radiofrequency pulses, and uses gradient coils to create readable signals. You do not need that answer unless you are buying an MRI. But the questions underneath (what breaks, what consumes helium, what needs calibration) are exactly the cost questions you need for any major device.

I ask every device vendor the same thing: Explain the operating-cost structure of your product to me the way you would explain how an MRI machine works. If they cannot identify the consumables, the failure modes, and the service intervals, then they have not thought about the product's total cost. I would rather get a detailed, honest answer, even from the expensive vendor, than a vague 'it is reliable' from the cheapest bid.

The same lesson in different clothes: ICD devices and surgical robots

An ICD device, or implantable cardioverter-defibrillator, is a small machine that monitors heart rhythm and delivers a shock if needed. A surgical robot is a large tool that helps surgeons operate through small incisions. They are very different products, but they have one procurement lesson in common: the cheap option is only cheap if you know exactly what you are giving up.

When we evaluated ICD devices, one manufacturer's list price was 7% lower. But the published data showed a slightly higher risk of lead complications. At our procedural volume, an extra two complications per 100 implants would erase the price advantage completely. As the FDA explains, Class III devices like ICDs require premarket approval. That is a stricter bar than 510(k) clearance, and it tells me something about the regulatory risk. The lower price was not a bargain; it was a bet that those complications would not happen.

Surgical robots are even worse for hidden costs. The robot itself is only part of the purchase. Instruments, service contracts, maintenance downtime, training, and operating-room turnover time all matter. There is a reason some hospitals end up with a robot that sits idle: the cost per case (including instruments, service, and training) was never calculated. My advice is to model cost per procedure, not cost per robot.

The checklist that fixed our process

After a product-switch mistake that cost us thousands in reeducation and duplicate orders, I built a 12-point checklist. The first item is not price. It is clinical evidence. Then training requirements, consumables, service intervals, and patient support programs. The last item is unit price.

This checklist is the cheapest insurance we have. It will not make the perfect decision every time, but it stops us from making the same stupid decision twice. A formal process matters. We did not have one before, and it cost us, literally, not just in time wasted.

Real talk: none of this is revolutionary. It is just discipline. But discipline is hard to maintain when a sales rep shows up with a pricing sheet that looks unbeatable. That is why I document everything: quotes, expected outcomes, actual failures. The data, not the sales narrative, gets the final vote.

When unit price still matters

Let me be honest about the limits of my argument. Total cost of ownership is not a reason to ignore price. For low-risk commodities with identical clinical outcomes, buy the cheapest responsible option. There are products where the risk stack is too low to justify a premium. The point is not 'always spend more.' It is 'know what the extra spending is buying, and what the savings cost you.'

Also, my data is from one health system. Your case mix, your staffing model, and your contract terms will change the numbers. The TCO spreadsheet is a thinking tool, not a universal truth.

As of 2025, the reimbursement landscape is tightening. Device budgets are under pressure. I do not think the answer is to squeeze every quote to the floor. I think the answer is to choose devices that have evidence behind them, support around them, and cost models that do not hide the expensive part in the follow-up visits.

The next time you see a price that looks too good, ask for the clinical data and the care program details. Ask how the device behaves when it is not new. Ask the MRI question. Then decide.